HOME >> BIOLOGY >> NEWS
HPV testing finds precancerous lesions at a higher rate than conventional pap smears

Human papillomavirus (HPV) testing was more sensitive than traditional Pap smears at detecting precancerous lesions of the cervix, a study in the June 7 issue of the Journal of the National Cancer Institute reports. A new, liquid-based form of the Pap test marginally improved sensitivity but also produced more false positives.

Previous studies have shown that searching for a precancerous cervical lesion called cervical intraepithelial neoplasia with an HPV test is more sensitive but also has more false positives than conventional pap smears, where doctors look for abnormal cells on a slide. Despite the widespread use of newer Pap technology called liquid-based cytology, where doctors first immerse the Pap sample in a solution before looking at the cells, its accuracy is not clearly defined. Some scientists suggest there is a need to understand what combination of tests increases sensitivity while keeping the number of false positives acceptable.

Guglielmo Ronco, M.D., Ph.D., of CPO Piemonte in Torino, Italy, and colleagues set up a randomized controlled trial that screened over 33,000 women for cervical cancer, half with conventional pap smears and the other half with HPV tests and liquid-based cytology. Women with abnormal cells from either Pap test or a positive HPV result were further examined by a technique called colposcopy, where doctors use a magnifying instrument to get a detailed view of the cervix.

The authors found that HPV testing combined with liquid-based cytology led to a 47% increase in sensitivity compared to conventional pap smears, but increased the chance of false positives by 60%. HPV testing alone increased sensitivity by more than 40%, with a smaller decrease in specificity (25% or 42%, depending on the type of test used). Liquid-based cytology did not show greater sensitivity than conventional pap smears, but increased the number of false positives.

The authors write, "HPV testing alone was more sensit
'"/>

Contact: Ariel Whitworth
jncimedia@oxfordjournals.org
301-841-1287
Journal of the National Cancer Institute
6-Jun-2006


Page: 1 2

Related biology news :

1. Modular leukemia drug shows promise in early testing
2. Rapid syphilis testing in Haiti will prevent congenital disease and stillbirths
3. XDx to present recent success with AlloMap molecular expression testing
4. Potential genetic testing for substance abuse raises hope, concern
5. U-M team: Genetic testing sheds light on degenerative eye disease
6. Antiretroviral resistance testing in HIV infected patients improves health and saves costs
7. Professors to develop hand-held pathogen testing device
8. Animal testing alternative has ticks trembling at the knees
9. New research to cut animal testing
10. New method of testing eggs for abnormalities could solve problems of embryo freezing
11. Education and guidelines needed for genetic testing in liver disease

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/18/2020)... ... 2020 , ... Commercial launch readiness is a critical stage in a product ... or vaccine, the global economic downturn will only increase price pressures overall for the ... capturing full value from every product launch is critical. However, history shows that only ...
(Date:7/2/2020)... CITY, Calif. (PRWEB) , ... July 01, 2020 ... ... biotech company, presented its phase 1a findings of Neihulizumab, a biologic for the ... conference in June 2020. Led by hemato-oncologist Dr. Paul J Martin of the ...
(Date:6/28/2020)... ... June 25, 2020 , ... ... solutions for biopharmaceutical R&D, today announced that it has entered into a ... multispecific antibodies (Multiclonics®), to support their translational and clinical research strategy to ...
Breaking Biology News(10 mins):
(Date:8/3/2020)... ... ... Introducing Ardent Animal Health – MediVet Biologics rebrands company and positions its platform ... Biologics since its formation in 2016, the company is relaunching itself under the Ardent ... its base of innovative therapies for osteoarthritis and cancer. , ...
(Date:7/31/2020)... ... July 29, 2020 , ... ... the launch of its new tagline, “BUILDING FOR LIFE.” The adoption of this ... around the globe, requiring fast track capacity to provide patients with urgently needed ...
(Date:7/31/2020)... (PRWEB) , ... July 29, 2020 , ... ... that can combine up to three different materials for use with CRM, neurostimulation, ... up to three materials to meet specific design requirements, performance, and cost criteria; ...
(Date:7/31/2020)... ... ... eSource has long been touted as the solution to high data management and monitoring ... did not take off as quickly as people initially expected, and where eSource is ... data electronically for clinical trials and then repurposing it for downstream analysis, at a ...
Breaking Biology Technology:
Cached News: